{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T21:10:14Z","timestamp":1781989814756,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.07.006","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T13:41:55Z","timestamp":1530970915000},"page":"5020-5029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants"],"prefix":"10.1016","volume":"36","author":[{"given":"Wei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.07.006_b0005","article-title":"The cell biology of rabies virus: using stealth to reach the brain","author":"Schnell","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.006_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001640","article-title":"The spatial and temporal dynamics of rabies in China","volume":"6","author":"Yu","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.006_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004874","article-title":"Human rabies in China, 1960\u20132014: a descriptive epidemiological study","volume":"10","author":"Zhou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2018.07.006_b0020","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.006_b0025","first-page":"133","article-title":"Influence of aluminum adjuvant to experimental rabies vaccine","volume":"13","author":"Lin","year":"1999","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.006_b0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4161\/hv.4.4.5588","article-title":"An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax\u00ae) in Indian subjects","volume":"4","author":"Sudarshan","year":"2014","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2018.07.006_b0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molimm.2017.02.011","article-title":"Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain","volume":"85","author":"Garg","year":"2017","journal-title":"Mol Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2018.07.006_b0040","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2008.01.043","article-title":"A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2018.07.006_b0045","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1016\/j.vaccine.2013.07.034","article-title":"Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX\u2122 adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques","volume":"31","author":"DiStefano","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.006_b0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2013.10.032","article-title":"Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles","volume":"173","author":"Li","year":"2014","journal-title":"J Control Release"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.07.006_b0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2011.06.002","article-title":"Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice","volume":"140","author":"Uto","year":"2011","journal-title":"Immunol Lett"},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.006_b0060","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.imbio.2013.05.006","article-title":"Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB\/c mice","volume":"218","author":"Hu","year":"2013","journal-title":"Immunobiology"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2018.07.006_b0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01378634","article-title":"A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects","volume":"131","author":"Lin","year":"1993","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.07.006_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijbiomac.2016.02.023","article-title":"Isatis indigotica root polysaccharides as adjuvants for an inactivated rabies virus vaccine","volume":"87","author":"Zhang","year":"2016","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.006_b0075","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.vaccine.2016.12.031","article-title":"An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers","volume":"35","author":"Wijaya","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.07.006_b0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/vim.2017.0093","article-title":"Enhanced immune response to rabies viruses by the use of a liposome adjuvant in vaccines","volume":"30","author":"Miao","year":"2017","journal-title":"Viral Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2018.07.006_b0085","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.vaccine.2006.09.026","article-title":"Development of lactococcal GEM-based pneumococcal vaccines","volume":"25","author":"Audouy","year":"2007","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2018.07.006_b0090","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1016\/j.vaccine.2006.02.040","article-title":"Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations","volume":"24","author":"Ramasamy","year":"2006","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2018.07.006_b0095","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2006.03.054","article-title":"Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization","volume":"24","author":"Audouy","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.006_b0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mi.2009.131","article-title":"Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection","volume":"3","author":"Ramirez","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.07.006_b0105","first-page":"1459394","article-title":"Adjuvants: classification, modus operandi, and licensing","volume":"2016","author":"Apostolico Jde","year":"2016","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.006_b0110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Garcon","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.006_b0115","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/hv.29375","article-title":"Evaluation of the immune response to RTS, S\/AS01 and RTS, S\/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive adults","volume":"10","author":"Leroux-Roels","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.006_b0120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4161\/hv.6.7.11883","article-title":"Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults","volume":"6","author":"Beran","year":"2010","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.006_b0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tube.2012.10.011","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD positive adults: a randomized controlled phase I\/II study","volume":"93","author":"Spertini","year":"2013","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.006_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59((R)) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O'Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.006_b0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the Adjuvant System story","volume":"13","author":"Garcon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.07.006_b0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7007-8-37","article-title":"Immune mechanisms of protection: can adjuvants rise to the challenge?","volume":"8","author":"McKee","year":"2010","journal-title":"BMC Biol"},{"key":"10.1016\/j.vaccine.2018.07.006_b0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2015.10.029","article-title":"A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies","volume":"489","author":"Zhang","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.07.006_b0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2016.10.002","article-title":"Ineffectiveness of rabies vaccination alone for post-exposure protection against rabies infection in animal models","volume":"135","author":"Zhang","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.07.006_b0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imlet.2016.05.016","article-title":"Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model","volume":"176","author":"Alipour Talesh","year":"2016","journal-title":"Immunol Lett"},{"issue":"51","key":"10.1016\/j.vaccine.2018.07.006_b0160","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1016\/j.vaccine.2017.10.097","article-title":"A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen","volume":"35","author":"Kalimuddin","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.006_b0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/1743-422X-8-521","article-title":"Molecular characterization of China rabies virus vaccine strain","volume":"8","author":"Jiao","year":"2011","journal-title":"Virol J"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.006_b0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ymeth.2005.09.015","article-title":"Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria","volume":"38","author":"van Roosmalen","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2018.07.006_b0175","unstructured":"Fang JH, Hora M. The adjuvant MF59: A 10-Year Perspective Gary Ott, Ramachandran Radhakrishnan. 2000; 42(2): pp. 211\u2013228."},{"key":"10.1016\/j.vaccine.2018.07.006_b0180","unstructured":"Laboratory techniques in rabies Fourth edition By World Health Organization, Geneva."},{"key":"10.1016\/j.vaccine.2018.07.006_b0185","first-page":"99","article-title":"Comparative studies of two potency tests for antirabies serum: neutralization test in mice (MNT) and rapid fluorescent focus inhibition test (RFFIT)","volume":"64","author":"Kurz","year":"1986","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2018.07.006_b0190","first-page":"137","article-title":"Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines","volume":"86","author":"Rooijakkers","year":"1996","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2018.07.006_b0195","first-page":"27(3)","article-title":"A simple method of estimating fifty per cent endpoints","author":"Reed","year":"1938","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.07.006_b0200","unstructured":"Xxii UP, Xvii N. US Pharmacopeial convention; 1990."},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.006_b0205","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/laban.988","article-title":"A novel adjuvant promises improved rabies vaccine","volume":"45","author":"Nicholson","year":"2016","journal-title":"Lab Anim (NY)"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.006_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000595","article-title":"Rabies-specific antibodies: measuring surrogates of protection against a fatal disease","volume":"4","author":"Moore","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.006_b0215","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/viro.1993.1261","article-title":"Mechanisms of rabies virus neutralization","volume":"194","author":"Flamand","year":"1993","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.006_b0220","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/iai.24.3.600-605.1979","article-title":"Kinetics of different specific immunological parameters after rabies vaccination in mice","volume":"24","author":"Blancou","year":"1979","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.07.006_b0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4615-1823-5_8","article-title":"Adjuvant properties of aluminum and calcium compounds","volume":"6","author":"Gupta","year":"1995","journal-title":"Pharm Biotechnol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.07.006_b0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imlet.2012.06.002","article-title":"Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro","volume":"147","author":"Ghimire","year":"2012","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.006_b0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","article-title":"Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol"},{"issue":"7198","key":"10.1016\/j.vaccine.2018.07.006_b0240","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.006_b0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.imlet.2005.08.002","article-title":"(How) do aluminium adjuvants work?","volume":"102","author":"Brewer","year":"2006","journal-title":"Immunol Lett"},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.006_b0250","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1021\/nn404211j","article-title":"Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles","volume":"7","author":"Sun","year":"2013","journal-title":"ACS Nano"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.07.006_b0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0264-410X(02)00435-8","article-title":"Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres","volume":"21","author":"Gutierro","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.006_b0260","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4161\/hv.4.1.4886","article-title":"A comparison of anionic nanoparticles and microparticles as vaccine delivery systems","volume":"4","author":"Wendorf","year":"2008","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.006_b0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.smim.2008.05.002","article-title":"T and B lymphocyte differentiation from hematopoietic stem cell","volume":"20","author":"Lai","year":"2008","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.006_b0270","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Garcon","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.07.006_b0275","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fimmu.2013.00282","article-title":"Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications","volume":"4","author":"Van Braeckel-Budimir","year":"2013","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.006_b0280","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.006_b0285","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14760584.2015.966085","article-title":"Vaccine adjuvant uses of poly-IC and derivatives","volume":"14","author":"Martins","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2018.07.006_b0290","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/ni.2078","article-title":"Solving vaccine mysteries: a systems biology perspective","volume":"12","author":"Trautmann","year":"2011","journal-title":"Nat Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:45Z","timestamp":1759400865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":58,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18309368"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}